No­var­tis bol­sters Plu­vic­to's case in prostate can­cer with PhI­II re­sults

The prog­no­sis is poor for metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) pa­tients. No­var­tis wants to change that by mak­ing its re­cent­ly ap­proved Plu­vic­to avail­able to pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER